Publications

A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN

Xiao W, Miles LA, Bowman RL, Durani V, Tian HS, DelGaudio NL, Mishra T, Zhu M, Zhang Y, Stump SE, Tallman MS, Levine RL, Cai SF

Blood Advances Dec 2020

Abstract

Myeloid neoplasm (MPN) clones can evolve from acute myeloid leukemia to gain dominance with isocitrate dehydrogenase inhibition. Pro-differentiation agents such as ivosidenib can unmask MPN sequelae.

VIEW

Area

Heme

Institution Type

Academia

Indication / Modality

Acute Myleoid Leukemia (AML), Myeloproliferative Neoplasms (MPN)

Goal of Study

Therapeutic Resistance

Key Genes

JAK2, IDH1

PAD Project

Analytes Assessed

InDels, SNV

Sample Storage

Fresh Frozen

Sample Prep

Whole Cells

Sample Type

Patient Material

Tissue / Organ

Bone Marrow Aspirates

Species

Human

Panel Used

Custom

Proof Point Demonstrated

Clonality, Co-occurrence

REQUEST QUOTE